Price
No data yet.
Social Signal Score
Analyst Ratings
23 analystsRevenue
$56.70M+1654.81%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Charles Jacobs
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 749
- Beta
- 2.44
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -5.47
Financials
Revenue
$56.70M+1654.8%Net Income
$-53.39MEBITDA
$-42.93MFree Cash Flow
$-74.14MEPS (diluted)
$-0.32Shares Outstanding (diluted)
164.57M+1114.3%Operating Expenses
$70.69MCash & Debt
$719.34MReturn of Capital
$8.16MRevenue by Segment (annual)
$1.37BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.12B | $440.30M | $2.72 |
| 2024 | $682.16M | $-187.50M | $-1.23 |
| 2023 | $556.38M | $-545.06M | $-5.41 |
| 2022 | $1.60B | $-657.94M | $-8.42 |
| 2021 | $197.58M | $-1.74B | $-23.44 |
| 2020 | $22.39M | $-418.26M | $-7.43 |
| 2019 | $18.66M | $-130.10M | $-5.40 |
| 2018 | $34.29M | $-184.75M | $-9.99 |
| 2017 | $31.18M | $-183.77M | $-12.56 |
| 2016 | $15.35M | $-279.97M | $-20.68 |
| 2015 | $36.25M | $-156.94M | $-11.97 |
| 2014 | $30.66M | $-82.95M | $-7.35 |
| 2013 | $20.91M | $-51.98M | $-6.13 |
| 2012 | $22.08M | $-28.51M | $-4.33 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $3.99
- Implied price
- $71.89
- Return from $12.75
- 41.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $35.74 — today's price is already 64.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 18.3% | 23.7% | 28.2% | 32.3% | 35.8% |
| 3.0% | 24.3% | 30.0% | 34.8% | 39.0% | 42.8% |
| 8.0% | 30.3% | 36.3% | 41.3% | 45.8% | 49.7% |
| 13.0% | 36.4% | 42.6% | 47.9% | 52.5% | 56.6% |
| 18.0% | 42.4% | 48.9% | 54.4% | 59.2% | 63.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
50+400.00%Social Signal Score
Mentions (21)
- Newszacks.com·19h ago·Neutral
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.
View source ↗ - News247wallst.com·4d ago·Positive
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies Vaccine and biotechnology names are leading a sharp sector rally, and a small protein-vaccine developer is posting the biggest gain of the group. Novavax (NASDAQ:NVAX) shares recently changed hands at $12.77, up 16%.
View source ↗ - Newszacks.com·5d ago·Neutral
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newszacks.com·7d ago·Positive
Novavax (NVAX) Stock Sinks As Market Gains: Here's Why In the latest trading session, Novavax (NVAX) closed at $11.27, marking a -10.31% move from the previous day.
View source ↗ - Newszacks.com·8d ago·Positive
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? Novavax (NVAX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
View source ↗ - Newsbenzinga.com·8d ago·Neutral
Novavax Shorts on Edge as Russia Plague Fears Spread A suspected plague death at a Siberian research institute has investors reaching for the pandemic playbook again. One of biotech's most heavily shorted stocks is posting the biggest gain.
View source ↗ - News247wallst.com·8d ago·Positive
Novavax Soars 22% as Sanofi Carries Nuvaxovid Into Vaccination Season; Moderna Climbs 8%, BioNTech Ticks Up Sanofi is carrying the Nuvaxovid COVID-19 shot into the fall vaccination season, and buyers are rewarding shares of licensor Novavax (NASDAQ:NVAX) far more heavily than the rest of biotech. Novavax stock has rose 17% during afternoon trading, reaching $12.
View source ↗ - Newszacks.com·15d ago·Negative
Novavax (NVAX) Rises As Market Takes a Dip: Key Facts In the closing of the recent trading day, Novavax (NVAX) stood at $10.79, denoting a +1.53% move from the preceding trading day.
View source ↗ - Newszacks.com·16d ago·Neutral
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
View source ↗ - Newszacks.com·25d ago·Positive
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know In the most recent trading session, Novavax (NVAX) closed at $10.11, indicating a +1.1% shift from the previous trading day.
View source ↗ - Newszacks.com·26d ago·Neutral
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock? Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
View source ↗ - Newszacks.com·32d ago·Neutral
Novavax (NVAX) Laps the Stock Market: Here's Why In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
View source ↗ - Newsmarketbeat.com·33d ago·Negative
Novavax Highlights Sanofi, Pfizer Catalysts in Matrix-M Platform Pivot Novavax NASDAQ: NVAX executives outlined the company's transition from a COVID-19 vaccine-focused business toward a partnership-driven model centered on its Matrix-M adjuvant technology, with near-term attention on Sanofi's commercial rollout of NUVAXOVID, combination vaccine development and early oncology research.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Novavax, Inc. (NVAX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsmarketbeat.com·34d ago·Neutral
Novavax Highlights Matrix-M Licensing Push, Oncology Ambitions at Cantor Conference Novavax NASDAQ: NVAX outlined its strategy to expand the use of its Matrix-M adjuvant platform through licensing partnerships, internal research programs and commercialization alliances, with management highlighting progress in infectious disease vaccines and early oncology work at the Cantor Healthcare Conference.
View source ↗ - Newsseekingalpha.com·34d ago·Positive
Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Novavax, Inc. (NVAX) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newsprnewswire.com·41d ago·Neutral
Novavax to Participate in September Investor Conferences GAITHERSBURG, Md., Sept. 2, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that company management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference, New YorkFireside chat on Wednesday, September 9, 2026, at 9:45 a.m.
View source ↗ - News247wallst.com·43d ago·Positive
Novavax Jumps 6% on Matrix-M Oncology Speculation: Is the Royalty Model the Real Story? Retail traders are treating Novavax as a cancer-vaccine play today, but the price action shows a single-name bid rather than a sector move. Novavax (NASDAQ:NVAX) stock is up 6% to $9.90 in midday trading.
View source ↗ - Newsbenzinga.com·44d ago·Neutral
Novavax Stock Climbs Monday: What's Going On? Shares of Novavax Inc. (NASDAQ:NVAX) are trading higher Monday morning. The stock is extending its 30% monthly gains as investors respond positively to regulatory approvals across major jurisdictions for its updated protein-based COVID-19 vaccine ahead of the 2026–2027 autumn vaccination campaign, alongside broader sector strength bolstered by positive late-stage oncology clinical trial results across the biotech landscape.
View source ↗ - Newsprnewswire.com·47d ago·Neutral
…file to global markets, providing an important option for healthcare providers and patients GAITHERSBURG, Md., Aug. 28, 2026 /PRNewswire/ -- Novavax, Inc.'s (Nasdaq: NVAX) partners have received approvals for the Nuvaxovid™ formulation to target the SARS-CoV-2 XFG variant for the 2026-2027 vaccination season in major markets including the U.S., European Union (EU) and Japan.
View source ↗ - Newsschaeffersresearch.com·48d ago·Negative
Novavax Stock Pulls Back After Milestone Vaccine Success Drug stock Novavax Inc (NASDAQ:NVAX) is trading 2.8% lower at $9.18 this afternoon, pulling back from yesterday's surge to six-week highs.
View source ↗
Earnings
Thu, Nov 5(in 3 weeks)
Consensus estimate $-0.22 per share
Typical surprise +76.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.32 vs $-0.38beat
- Wed, May 6$-0.06 vs $-0.25beat
- Thu, Feb 26$0.11 vs $-0.66beat
- Thu, Nov 6$-1.25 vs $-1.08miss
- Wed, Aug 6$0.62 vs $-0.07beat
- Thu, May 8$2.93 vs $0.71beat
Estimates and results for NVAX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NVAX officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Charles Patrick Robertssenate · KS · disclosed Nov 5, 2020 (23d later)Sell$1,001 - $15,000
- Charles Patrick Robertssenate · KS · disclosed Aug 30, 2020 (13d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.